Drug discovery specialists at Ligand take their antibody biz public via SPAC, aiming to build $850M company

When Ligand Pharmaceuticals unveiled plans to spin off its antibody discovery unit, OmniAb, last November, the board of directors had yet to approve a specific format for the split. The leading option, Ligand said at the time, was an IPO and distribution of shares to existing shareholders.